Autotaxin (ATX) is a potential target for the treatment of various cancers. A new series of ATX inhibitors was rationally designed and synthesized based on our previous study. Biological evaluation and structure-activity relationship (SAR) of this series are discussed. Among fourteen synthesized derivatives, six compounds (2, 3, 4, 12, 13 and 14) exhibited enhanced ATX inhibitory activities with IC50
Autotaxin(ATX)是治疗各种癌症的潜在靶标。在之前的研究基础上,合理设计和合成了一系列新的ATX
抑制剂。讨论了该系列的
生物评价和构效关系(
SAR)。间14个合成衍
生物,六种化合物(2,3,4,12,13和14)表现出增强的ATX抑制活性与IC 50值在低纳摩尔范围内。通过分子对接研究了ATX活性位点内所有合成化合物的分子相互作用。在本文中,我们描述了导致优化ATX
抑制剂(化合物4的IC 50 = 1.23 nM,FS-3和2.18 nM,bis-pNPP)鉴定的先导优化工作。此外,分析了这种最有前途的化合物的药代动力学特性。